Early Identification and Treatment of Rare Cardiomyopathy Cohorts

Launched by RENJI HOSPITAL · Jan 21, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on improving how we identify and treat rare types of heart conditions known as cardiomyopathies, which include hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), metabolic cardiomyopathy, and restrictive cardiomyopathy. Researchers will create a detailed database that includes various patient information, blood samples, heart tissue samples, and imaging results. They aim to find specific markers or signs that indicate changes in the heart's condition, helping to develop a better way to assess the risk of heart failure in patients. By doing this, the goal is to provide more precise prevention strategies for heart failure based on individual risk.

To be eligible for this trial, participants must be between 18 and 75 years old and have been preliminarily diagnosed with heart failure, meaning their heart isn't pumping blood as well as it should. They should also not have any other significant heart diseases or serious kidney problems. Participants can expect to undergo various assessments, including heart imaging, and they will need to give their consent to join the study. This trial is not yet recruiting, but it aims to gather important data that could lead to better treatment options for those with these rare heart conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18-75 years old.
• • Patients preliminarily diagnosed with heart failure and scheduled to receive drug therapy after being evaluated by cardiology departments.
• • No history of structural heart disease, and the Framingham score \<5 (for patients with the Framingham score ≥5, coronary artery disease will be excluded by coronary angiography/coronary CT/exercise platelet).
• • Creatinine clearance ≥50ml/min (Cockcroft-Gault formula).
• • LVEF ≥50% assessed by Echocardiography.
• • QT interval \< 470 ms.
• • Providing written informed consent.
• Exclusion Criteria:
• • Presence of acute/chronic renal impairment (GFR \<50/ml/min/1.73m2).
• • History of cardiovascular disease such as confirmed coronary artery disease, valvular disease, cardiomyopathy, congenital heart disease, and heart failure.
• • Presence of contraindications to CMR.